Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation

Int J Pharm. 2023 Aug 25:643:123230. doi: 10.1016/j.ijpharm.2023.123230. Epub 2023 Jul 16.

Abstract

Liposomes are promising drug carriers for a wide range of central nervous system disorders, such as Parkinson's disease (PD), since they can protect active substances from degradation and could be administered intranasally, ensuring a direct access to the brain. Levodopa (LD), the drug commonly used to treat PD, spontaneously oxidizes in aqueous solutions and thus needs to be stabilized. Our investigation focuses on the preparation and the physico-chemical characterization of mixed liposomes to vehiculate LD and two natural substances (L-ascorbic acid and quercetin) that can prevent its oxidation and contribute to the treatment of Parkinson's disease. These co-loaded vesicles were prepared using a saturated phospholipid and structurally related cationic or analogue N-oxide surfactants and showed different properties, based on their composition. In particular, ex-vivo permeability tests using porcine nasal mucosa were performed, denoting that subtle variations of the lipids structure can significantly affect the delivery of LD to the target site.

Keywords: Antiradical activity; Intranasal delivery; Levodopa; Liposomes; N-oxide moiety; Parkinson’s disease.

MeSH terms

  • Ascorbic Acid
  • Drug Carriers / chemistry
  • Humans
  • Levodopa* / therapeutic use
  • Liposomes / chemistry
  • Parkinson Disease* / drug therapy

Substances

  • Levodopa
  • Liposomes
  • Drug Carriers
  • Ascorbic Acid